Optimization of Cyclosporin therapy in atopic dermatitis through multiomic predictive models of treatment response (DermAtOmics) - DermAtOmics

Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz0 个研究点目标入组 100 人开始时间: 2022年6月13日最近更新: 2024年8月21日

适应症

试验速览

暂无简介。

•For cohort 1. Subjects diagnosed with moderate-severe atopic dermatitis who are going to receive treatment with cyclosporine., For Cohort 1 and 2. Participants must be willing and able to provide written informed consent prior the initiation of any study procedures, For Cohort 1 and 2. For children, parent/legal guardian must provide written informed consent. If age >11 years old, the minor must give assent., For Cohort 1 and 2. Participant is willing and able to adhere to the procedures specified in this protocol, For Cohort 2. Subjects diagnosed with moderate-severe atopic dermatitis who are receiving or have received in the past cyclosporine therapy.

•Subjects participating in a clinical trial in the last three months., Any condition or situation precluding or interfering the compliance with the protocol., Women of childbearing potential must have a negative urine pregnancy test at Screening and Day 0., Women of childbearing potential must commit not to become pregnant

发起方

Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz